Skip to main content

Table 3 Treatment-emergent adverse events (N = 16)

From: Efficacy and safety of dacomitinib in treatment-naïve patients with advanced NSCLC harboring uncommon EGFR mutation: an ambispective cohort study

Adverse events

All Grade (n, %)

Grade 1 (n, %)

Grade 2 (n, %)

 ≥ Grade 3 (n, %)

Oral ulcer

8 (50.0)

4 (25.0)

4 (25.0)

0

Rash

14 (87.5)

6 (37.5)

8 (50.0)

0

Paronychia

10 (62.5)

9 (56.3)

1 (6.2)

0

Diarrhea

8 (50.0)

7 (43.8)

1 (6.3)

0

Interstitial pneumonia

0

0

0

0